|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2008
Lung cancer gene associated with COPD: triple whammy or possible confounding effect?
1 Dept of Medicine, University of Auckland, 2 Synergenz Biosciences Ltd, Auckland, and 3 Dept of Medicine, University of Otago, Christchurch, New Zealand.
CORRESPONDENCE: R. P. Young, Dept of Medicine, Auckland Hospital, Private Bag 92019, Auckland, New Zealand. Fax: 64 96236456. E-mail: roberty{at}adhb.govt.nz
Keywords: Association study, chronic obstructive pulmonary disease, confounding, lung cancer, nicotinic acetylcholine receptor, polymorphism
Received: June 19, 2008
Accepted August 18, 2008
Recently, several large genome-wide association studies have identified a putative "lung cancer" locus in the nicotinic acetylcholine receptor subunit genes (nAChR) on 15q25. However, these findings may be confounded by the presence of chronic obstructive pulmonary disease (COPD), which is also strongly associated with smoking exposure and lung cancer. This is likely as the prevalence of COPD in lung cancer cohorts is as much as two-fold greater than that reported in smoking control populations (50 versus 20%).
The present authors compared the genotype frequencies of the most strongly associated single nucleotide polymorphism (rs16969968) in the
The AA genotype was found to be more frequent and was seen in 437 (16%) lung cancer cases and 445 (14%) COPD cases compared with 475 (9%) healthy smoking controls. More importantly, when 429 lung cancer cases were divided according to spirometry results (performed within 3 months of diagnosis, prior to surgery and in the absence of effusions or collapse), the AA genotype was present in 19 and 11% of cases with and without COPD, respectively.
These findings suggest that the association between the
5 subunit of the nAChR gene cluster between three matched smoking cohorts. 5 subunit nicotinic acetylcholine receptor single nucleotide polymorphism and lung cancer may, in part, be confounded by chronic obstructive pulmonary disease.
This article has been cited by other articles:
|
|
 |
|
  Y R B M van Gestel, S E Hoeks, D D Sin, V Huzeir, H Stam, F W Mertens, R T van Domburg, J J Bax, and D Poldermans COPD and cancer mortality: the influence of statins Thorax, November 1, 2009; 64(11): 963 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Smolonska, C. Wijmenga, D. S. Postma, and H. M. Boezen Meta-analyses on Suspected Chronic Obstructive Pulmonary Disease Genes: A Summary of 20 Years' Research Am. J. Respir. Crit. Care Med., October 1, 2009; 180(7): 618 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R P Young, R J Hopkins, B A Hay, M J Epton, G D Mills, P N Black, H D Gardner, R Sullivan, and G D Gamble A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers Postgrad. Med. J., October 1, 2009; 85(1008): 515 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Silverman, A. Spira, and P. D. Pare Genetics and Genomics of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 15, 2009; 6(6): 539 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Young, R. J. Hopkins, T. Christmas, P. N. Black, P. Metcalf, and G. D. Gamble COPD prevalence is increased in lung cancer, independent of age, sex and smoking history Eur. Respir. J., August 1, 2009; 34(2): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R P Young, R Hopkins, and T E Eaton Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence Postgrad. Med. J., August 1, 2009; 85(1006): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Brambilla and A. Gazdar Pathogenesis of lung cancer signalling pathways: roadmap for therapies Eur. Respir. J., June 1, 2009; 33(6): 1485 - 1497. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |